MedPath

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Phase 2
Active, not recruiting
Conditions
Triple Negative Breast Neoplasms
Interventions
Registration Number
NCT04191135
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are:

1. Olaparib plus pembrolizumab is superior to chemotherapy plus pembrolizumab with respect to progression-free survival (PFS).

2. Olaparib plus pembrolizumab is superior to chemotherapy plus pembrolizumab with respect to overall survival (OS).

As of Amendment 3, study enrollment was discontinued. Participants who were receiving benefit from the study intervention could continue treatment until criteria for discontinuation are met. Participants who are on study treatment or in follow-up phase will no longer have tumor response assessments by BICR.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
462
Inclusion Criteria

Induction Period:

  • Has locally recurrent inoperable TNBC that has not previously been treated with chemotherapy and that cannot be treated with curative intent OR has metastatic TNBC that has not been previously treated with chemotherapy
  • Has been treated with anthracycline and/or a taxane in the neoadjuvant/adjuvant setting, if they received systemic treatment in the neoadjuvant/adjuvant setting, unless anthracycline and/or taxane was contraindicated or not considered the best treatment option for the participant in the opinion of the treating physician
  • Has measurable disease based on RECIST 1.1
  • Has provided a recently obtained or archival (no more than 3 years old) core or excisional biopsy of a tumor lesion not previously irradiated
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 as assessed within 7 days prior to the start of induction study treatment
  • Has a life expectancy ≥27 weeks from the day of first study treatment
  • Demonstrate adequate organ function within 10 days prior to the start of study treatment
  • A male participant must agree to be abstinent or use contraception and refrain from donating sperm during the intervention period and for at least the time needed to eliminate each study intervention (95 days for olaparib and chemotherapy; no requirement for pembrolizumab)
  • A female participant must not be pregnant or breastfeeding and must agree to the following if is a woman of childbearing potential (WOCBP): have a negative pregnancy test within 24 hours before the start of study treatment and agree to be abstinent or use contraception and refrain from donating eggs (ova, oocytes) during the intervention period and for at least the time needed to eliminate each study intervention (180 days for olaparib and chemotherapy; 120 days for pembrolizumab)

Post-induction Period:

  • Has received up to 6 cycles but not less than 4 cycles of induction therapy without permanently discontinuing from pembrolizumab or both carboplatin and gemcitabine
  • Has achieved complete response (CR), partial response (PR), or stable disease (SD) based on RECIST 1.1 by Blinded Independent Central Review (BICR) at the Week 18 evaluation
  • Is able to complete during post-induction at least the Cycle 1, Day 1 doses of olaparib and pembrolizumab or the Cycle 1, Day 1 doses of at least one of the chemotherapy agents being administered at the end of induction (carboplatin and/or gemcitabine) in addition to pembrolizumab
  • Has ECOG performance status of 0 or 1, as assessed within 7 days prior to the start of post-induction study treatment
  • Has no higher than Grade 1 toxicities related to induction therapy (excluding alopecia) prior to randomization
Exclusion Criteria

Induction Period:

  • Has a known additional malignancy that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, cervical cancer in situ) that have undergone potentially curative therapy
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML
  • Has a history of (non-infectious) pneumonitis\interstitial lung disease that required steroids or current pneumonitis\interstitial lung disease
  • Has active, or a history of, interstitial lung disease
  • Has a known history of active tuberculosis
  • Has an active infection requiring systemic therapy
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
  • Has a history of class II-IV congestive heart failure or myocardial infarction within 6 months of first study treatment
  • Has neuropathy ≥Grade 2
  • Has not recovered (eg, to ≤Grade 1 or to baseline) from AEs due to a previously administered therapy
  • Has a known history of hypersensitivity or allergy to pembrolizumab, olaparib and any of its components, and/or to any of the study chemotherapies (eg, carboplatin or gemcitabine) and any of their components
  • Has severe hypersensitivity (≥Grade 3) to the study treatments and/or any of their excipients
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the Screening Visit through 180 days after the last dose of study treatment
  • Is a WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation
  • Has received prior therapy with either olaparib or any other poly adenosine diphosphate ribose polymerase (PARP) inhibitor
  • Has received prior radiotherapy within 2 weeks of start of study treatment
  • Has received colony-stimulating factors (eg, granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment
  • Has had an allogenic tissue/solid organ transplant.
  • Has received previous allogenic bone marrow transplant or double umbilical cord transplantation (dUCBT)
  • Has had major surgery within 2 weeks of starting study treatment or has not recovered from any effects of any major surgery
  • Has received a live or live-attenuated vaccine within 30 days prior to first study treatment
  • Is receiving any medication prohibited in combination with study chemotherapies unless medication was stopped within 7 days prior to first study treatment
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T cell receptor (such as cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137) or has previously participated in a study evaluating pembrolizumab regardless of treatment received
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has presence of uncontrolled, potentially reversible cardiac conditions, as judged by the investigator
  • Has a history or current evidence of any condition (eg, cytopenia, transfusion-dependent anemia, or thrombocytopenia), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's involvement for the full duration of the study, or is not in the best interest of the participant to be involved, in the opinion of the treating investigator
  • Is either unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, malabsorption)
  • Is unlikely to comply with the study procedures, restrictions, and requirements of the study; as judged by the investigator

Post-induction Period:

  • Has severe hypersensitivity (≥Grade 3) to the study treatments and/or any of their excipients
  • Has permanently discontinued from both carboplatin and gemcitabine during induction due to toxicity
  • Has permanently discontinued from pembrolizumab during induction due to toxicity
  • Has received less than 4 cycles of chemotherapy plus pembrolizumab during induction
  • Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study
  • Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pembrolizumab + OlaparibPembrolizumabThis arm includes participants who randomized following completion of the induction period. After the induction period, participants received pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
Pembrolizumab + Carboplatin + GemcitabinePembrolizumabThis arm includes participants who randomized following completion of the induction period. Participants continued to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m\^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
Pembrolizumab + Carboplatin + GemcitabineCarboplatinThis arm includes participants who randomized following completion of the induction period. Participants continued to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m\^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
Pembrolizumab + Carboplatin + GemcitabineGemcitabineThis arm includes participants who randomized following completion of the induction period. Participants continued to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m\^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.
Pembrolizumab + OlaparibOlaparibThis arm includes participants who randomized following completion of the induction period. After the induction period, participants received pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS)Up to approximately 29 months

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS is reported based on the product-limit (Kaplan-Meier) method for censored data.

Overall Survival (OS)Up to approximately 29 months

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. OS is reported based on the product-limit (Kaplan-Meier) method for censored data.

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS) in Participants With PD-L1 Positive Tumors With a CPS ≥10Up to approximately 29 months

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Only participants with a CPS ≥10 were included in this analysis.

Progression-Free Survival (PFS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors With a Combined Positive Score (CPS) ≥10Up to approximately 29 months

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Only participants with a CPS ≥10 were included in this analysis. PFS is reported based on the product-limit (Kaplan-Meier) method for censored data.

PFS in Participants With Breast Cancer Susceptibility Gene Mutation (BRCAm) TumorsUp to approximately 29 months

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Only participants with BRCAm-positive tumors were included in this analysis. PFS is reported based on the product-limit (Kaplan-Meier) method for censored data.

Change From Baseline in Emotional Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 21-24 ScoreBaseline and week 18

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 4 questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Change from baseline in emotional functioning (EORTC QLQ-C30 Items 21-24) score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1) and BRCA status at randomization (BRCAm vs. BRCAwt)) as covariates.

Change From Baseline in Systemic Therapy Side Effects Using the European Organization for Research and Treatment of Cancer Breast Cancer-Specific QoL Questionnaire (EORTC QLQ-BR23) Items 1-4, 6, 7, and 8 ScoreBaseline and week 18

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30, consisting of functional scales (body image, sexual enjoyment, sexual functioning, future perspective) and symptom scales (systemic therapy side effects, upset by hair loss, arm symptoms, breast symptoms). Participant responses to 7 questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All, 4=Very Much). Using linear transformation, raw scores are standardized, so scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in systemic therapy side effects (EORTC QLQ-BR23 Items 1-4, 6, 7, and 8) score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1) and BRCA status at randomization (BRCAm vs. BRCAwt)) as covariates.

OS in Participants With BRCAm TumorsUp to approximately 29 months

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Only participants with BRCAm-positive tumors were included in this analysis.

Change From Baseline in Health-Related Quality-of-Life (QoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Combined ScoreBaseline and week 18

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the QoL question "How would you rate your overall quality of life during the past week?" (Item 30) were each scored on a 7-point scale (1=Very Poor to 7=Excellent), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1) and BRCA status at randomization (BRCAm vs. BRCAwt)) as covariates.

Change From Baseline in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 ScoreBaseline and week 18

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. The change from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1) and BRCA status at randomization (BRCAm vs. BRCAwt)) as covariates.

Change From Baseline in Visual Analogue Scale (VAS) Score on the European Quality of Life 5-dimension, 5-level Questionnaire (EQ-5D-5L)Baseline and week 18

The EQ-5D-5L is a questionnaire developed to assess health-related outcomes. The VAS is a component of the EQ-5D-5L that asks participants to rate their overall health on a vertical visual analogue scale, with the scale's ends labelled 'The best health you can imagine' (equivalent to a score of 0) and 'The worst health you can imagine' (equivalent to a score of 100). The change from baseline in VAS score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1) and BRCA status at randomization (BRCAm vs. BRCAwt)) as covariates.

Change From Baseline in Health-Related QoL Using the EORTC QLQ-C30 Items 29 and 30 Combined Score in Participants With Breast Cancer Susceptibility Gene Mutation (BRCAm) TumorsBaseline and up to 18 weeks

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the QoL question "How would you rate your overall quality of life during the past week?" (Item 30) were each scored on a 7-point scale (1=Very Poor to 7=Excellent), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scores was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), and baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1)) as covariates.

Change From Baseline in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score in Participants With BRCAm TumorsBaseline and week 18

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. The change from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score was calculated based on a constrained longitudinal data analysis (cLDA) model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), and baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1)) as covariates.

Change From Baseline in Emotional Functioning Using the EORTC QLQ-C30 Items 21-24 Score in Participants With BRCAm TumorsBaseline and week 18

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 4 questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. The change from baseline in emotional functioning (EORTC QLQ-C30 Items 21-24) score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), and baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1)) as covariates.

Change From Baseline in Systemic Therapy Side Effects Using the EORTC QLQ-BR23 Items 1-4, 6, 7, and 8 Score in Participants With BRCAm TumorsBaseline and week 18

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30, consisting of functional scales (body image, sexual enjoyment, sexual functioning, future perspective) and symptom scales (systemic therapy side effects, upset by hair loss, arm symptoms, breast symptoms). Participant responses to 7 questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All, 4=Very Much). Using linear transformation, raw scores are standardized, so scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in systemic therapy side effects (EORTC QLQ-BR23 Items 1-4, 6, 7, and 8) score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), and baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1)) as covariates.

Change From Baseline in Visual Analogue Scale (VAS) Score on the EQ-5D-5L in Participants With BRCAm TumorsBaseline and week 18

The EQ-5D-5L is a questionnaire developed to assess health-related outcomes. The VAS is a component of the EQ-5D-5L that asks participants to rate their overall health on a vertical visual analogue scale, with the scale's ends labelled 'The best health you can imagine' (equivalent to a score of 0) and 'The worst health you can imagine' (equivalent to a score of 100). The change from baseline in VAS score was calculated based on a cLDA model with scores as response variable with covariates for treatment by time interaction, stratification factors (response at randomization (CR/PR vs. SD), and baseline CPS for PD-L1 expression (PD-L1 CPS\<1 vs. PD-L1 CPS≥1)) as covariates.

Time to Deterioration (TTD) in Health-Related QoL Using the EORTC QLQ-C30 Items 29 and 30 ScoreBaseline and up to approximately 29 months

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the QoL question "How would you rate your overall quality of life during the past week?" (Item 30) were each scored on a 7-point scale (1=Very Poor to 7=Excellent), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in Items 29 and 30 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 ScoreUp to approximately 29 months

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in physical functioning Items 1 to 5 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Emotional Functioning Using the EORTC QLQ-C30 Items 21-24 ScoreUp to approximately 29 months

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 4 questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in emotional functioning Items 21-24 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Systemic Therapy Side Effects Using the EORTC QLQ-BR23 Items 1-4, 6, 7, and 8 ScoreUp to approximately 29 months

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective) and four symptom scales (systemic therapy side effects, upset by hair loss, arm symptoms, breast symptoms). Participant responses to 7 questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in systemic therapy side effects Items 1-4, 6, 7 and 8 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Health-Related QoL Using the EORTC QLQ-C30 Items 29 and 30 Score in Participants With Breast Cancer Susceptibility Gene Mutation (BRCAm) TumorsBaseline and up to approximately 29 months

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the Global Health Status (GHS) question "How would you rate your overall health during the past week?" (Item 29) and the QoL question "How would you rate your overall quality of life during the past week?" (Item 30) were each scored on a 7-point scale (1=Very Poor to 7=Excellent), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in Items 29 and 30 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Physical Functioning Using the EORTC QLQ-C30 Items 1- 5 Score in Participants With BRCAm TumorsUp to approximately 29 months

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in physical functioning Items 1 to 5 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Emotional Functioning Using the EORTC QLQ-C30 Items 21-24 Score in Participants With BRCAm TumorsUp to approximately 29 months

EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to 4 questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much), then summed. Summed raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in emotional functioning Items 21-24 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

TTD in Systemic Therapy Side Effects Using the EORTC QLQ-BR23 Items 1-4, 6, 7, and 8 Score in Participants With BRCAm TumorsUp to approximately 29 months

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective) and four symptom scales (systemic therapy side effects, upset by hair loss, arm symptoms, breast symptoms). Participant responses to 7 questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. TTD was defined as the time from baseline to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in systemic therapy side effects Items 1-4, 6, 7 and 8 scale scores. TTD is reported based on the product-limit (Kaplan-Meier) method for censored data.

Number of Participants Who Experienced At Least One Adverse Event (AE)Up to approximately 29 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience at least 1 AE is presented.

Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)Up to approximately 29 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented.

Trial Locations

Locations (122)

University of Chicago ( Site 0159)

🇺🇸

Chicago, Illinois, United States

Raigmore Hospital ( Site 0915)

🇬🇧

Inverness, Highland, United Kingdom

Zhytomyr Regional Oncology Center ( Site 1515)

🇺🇦

Zhytomyr, Zhytomyrska Oblast, Ukraine

Institut Sainte Catherine ( Site 1026)

🇫🇷

Avignon, Vaucluse, France

Clinica de la Costa Ltda. ( Site 0600)

🇨🇴

Barranquilla, Atlantico, Colombia

Institut Claudius Regaud IUCT Oncopole ( Site 1001)

🇫🇷

Toulouse, Haute-Garonne, France

Centro Investigación del Cáncer James Lind ( Site 0510)

🇨🇱

Temuco, Araucania, Chile

Pontificia Universidad Catolica de Chile ( Site 0501)

🇨🇱

Santiago, Region M. De Santiago, Chile

CHU Amiens Hopital Sud ( Site 1023)

🇫🇷

Amiens, Somme, France

Institut Gustave Roussy ( Site 1010)

🇫🇷

Villejuif, Val-de-Marne, France

Fundacion Valle del Lili ( Site 0602)

🇨🇴

Cali, Valle Del Cauca, Colombia

Organizacion Clinica Bonnadona-Prevenir S.A.S. ( Site 0609)

🇨🇴

Barranquilla, Atlantico, Colombia

Centre Henri Becquerel ( Site 1020)

🇫🇷

Rouen, Seine-Maritime, France

Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 1607)

🇭🇺

Pecs, Baranya, Hungary

CI Krivorizhskiy oncology dispensery ( Site 1504)

🇺🇦

Kryviy Rih, Dnipropetrovska Oblast, Ukraine

Hemato Oncologos S.A. ( Site 0603)

🇨🇴

Cali, Valle Del Cauca, Colombia

Oncocentro ( Site 0502)

🇨🇱

Vina del Mar, Valparaiso, Chile

Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0601)

🇨🇴

Medellin, Antioquia, Colombia

Oncomedica S.A. ( Site 0606)

🇨🇴

Monteria, Cordoba, Colombia

Koo Foundation Sun Yat-Sen Cancer Center ( Site 2300)

🇨🇳

Taipei, Taiwan

Jewish General Hospital ( Site 0010)

🇨🇦

Montreal, Quebec, Canada

Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0161)

🇺🇸

Middletown, New Jersey, United States

St. Joseph Heritage Healthcare ( Site 0104)

🇺🇸

Santa Rosa, California, United States

Pacific Cancer Care ( Site 0142)

🇺🇸

Monterey, California, United States

Massachusetts General Hospital ( Site 0155)

🇺🇸

Boston, Massachusetts, United States

Virginia Piper Cancer Institute ( Site 0157)

🇺🇸

Minneapolis, Minnesota, United States

Memorial Sloan-Kettering Cancer Center at Commack ( Site 0160)

🇺🇸

Commack, New York, United States

Memorial Sloan-Kettering Cancer Center ( Site 0156)

🇺🇸

New York, New York, United States

Texas Oncology-New Braunfels ( Site 0168)

🇺🇸

New Braunfels, Texas, United States

Texas Oncology - San Antonio Stone Oak ( Site 0166)

🇺🇸

San Antonio, Texas, United States

Virginia Oncology Associates ( Site 0163)

🇺🇸

Newport News, Virginia, United States

Virginia Oncology Associates ( Site 0153)

🇺🇸

Norfolk, Virginia, United States

Princess Margaret Cancer Centre ( Site 0005)

🇨🇦

Toronto, Ontario, Canada

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0003)

🇨🇦

Montreal, Quebec, Canada

YVMH dba Virginia Mason Memorial/North Star Lodge Cancer Center ( Site 0128)

🇺🇸

Yakima, Washington, United States

CSSS de Laval- Hopital de la Cite de la Sante ( Site 0011)

🇨🇦

Laval, Quebec, Canada

McGill University Health Centre ( Site 0002)

🇨🇦

Montreal, Quebec, Canada

CHU-Jean Minjoz ( Site 1013)

🇫🇷

Besancon, Doubs, France

Centre Francois Baclesse ( Site 1012)

🇫🇷

Caen, Calvados, France

CHR-METZ-THIONVILLE - Hopital de Mercy ( Site 1007)

🇫🇷

Metz, Moselle, France

Centre de Cancerologie du Grand Montpellier ( Site 1009)

🇫🇷

Montpellier, Languedoc-Roussillon, France

Centre Leon Berard ( Site 1018)

🇫🇷

Lyon, Rhone, France

Hôpital Saint-Louis ( Site 1025)

🇫🇷

Paris, France

Hochwaldkrankenhaus Bad Nauheim ( Site 1211)

🇩🇪

Bad Nauheim, Hessen, Germany

Gynaekologisches Zentrum-Schwerpunkt Gyn. Onkologie ( Site 1205)

🇩🇪

Bonn, Nordrhein-Westfalen, Germany

Kliniken Essen-Mitte ( Site 1215)

🇩🇪

Essen, Nordrhein-Westfalen, Germany

Sana Klinikum Offenbach Klinik fuer Gynakologie und Geburtshilfe ( Site 1206)

🇩🇪

Offenbach am Main, Hessen, Germany

Gynaekologisch-onkologische Praxis Hannover ( Site 1207)

🇩🇪

Hannover, Niedersachsen, Germany

Orszagos Onkologiai Intezet ( Site 1602)

🇭🇺

Budapest, Hungary

Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1601)

🇭🇺

Szolnok, Jasz-Nagykun-Szolnok, Hungary

Debreceni Egyetem Klinikai Kozpont ( Site 1600)

🇭🇺

Debrecen, Hungary

Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1604)

🇭🇺

Kaposvar, Hungary

Cork University Hospital ( Site 0902)

🇮🇪

Cork, Ireland

Hiroshima City Hiroshima Citizens Hospital ( Site 2204)

🇯🇵

Hiroshima, Japan

Severance Hospital Yonsei University Health System ( Site 2401)

🇰🇷

Seoul, Korea, Republic of

Seoul National University Bundang Hospital ( Site 2409)

🇰🇷

Seongnam-si, Kyonggi-do, Korea, Republic of

Clinica Universitaria Navarra - Madrid ( Site 0700)

🇪🇸

Madrid, Spain

Seoul National University Hospital ( Site 2403)

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center ( Site 2404)

🇰🇷

Seoul, Korea, Republic of

Regionalny Szpital Specjalistyczny Latawiec ( Site 1917)

🇵🇱

Swidnica, Dolnoslaskie, Poland

Pratia MCM Krakow ( Site 1919)

🇵🇱

Krakow, Malopolskie, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (Site 1908)

🇵🇱

Warszawa, Mazowieckie, Poland

Hospital Clinic I Provincial de Barcelona ( Site 0702)

🇪🇸

Barcelona, Spain

Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1912)

🇵🇱

Gliwice, Slaskie, Poland

Hospital General Arnau de Vilanova de Valencia ( Site 0706)

🇪🇸

Valencia, Valenciana, Comunitat, Spain

Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1913)

🇵🇱

Gdynia, Pomorskie, Poland

Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 1909)

🇵🇱

Pleszew, Wielkopolskie, Poland

China Medical University Hospital ( Site 2302)

🇨🇳

Taipei, Taiwan

National Cheng Kung University Hospital ( Site 2303)

🇨🇳

Tainan, Taiwan

Kaohsiung Chang Gung Memorial Hospital ( Site 2304)

🇨🇳

Kaohsiung, Taiwan

MacKay Memorial Hospital ( Site 2301)

🇨🇳

Taipei, Taiwan

Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 1508)

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 1502)

🇺🇦

Dnipro, Dnipropetrovska Oblast, Ukraine

Communal non profit enterprise Regional Clinical Oncology Center ( Site 1512)

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

MI Precarpathian Clinical Oncology Center ( Site 1506)

🇺🇦

Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine

SI-Zaytsev institute of general and urgent surgery-NAMS ( Site 1518)

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

Medical Centre LLC Oncolife ( Site 1510)

🇺🇦

Zaporizhzhya, Zaporizka Oblast, Ukraine

Medical Center Verum ( Site 1501)

🇺🇦

Kyiv, Ukraine

The Christie NHS Foundation Trust ( Site 0914)

🇬🇧

Manchester, United Kingdom

Blackpool Victoria Hospital ( Site 0921)

🇬🇧

Blackpool, Lancashire, United Kingdom

Barts Health NHS Trust ( Site 0912)

🇬🇧

London, London, City Of, United Kingdom

Musgrove Park Hospital ( Site 0918)

🇬🇧

Taunton, Somerset, United Kingdom

Texas Oncology-San Antonio Medical Center ( Site 0158)

🇺🇸

San Antonio, Texas, United States

Texas Oncology-San Antonio Northeast ( Site 0165)

🇺🇸

San Antonio, Texas, United States

UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0138)

🇺🇸

San Francisco, California, United States

Universitaetsklinikum Carl Gustav Carus ( Site 1203)

🇩🇪

Dresden, Sachsen, Germany

Zala Megyei Szent Rafael Korhaz ( Site 1605)

🇭🇺

Zalaegerszeg, Zala, Hungary

John Wayne Cancer Institute ( Site 0111)

🇺🇸

Santa Monica, California, United States

Henry Ford Health System ( Site 0103)

🇺🇸

Detroit, Michigan, United States

University of Miami Sylvester CC ( Site 0146)

🇺🇸

Miami, Florida, United States

Georgia Cancer Center at Augusta University ( Site 0129)

🇺🇸

Augusta, Georgia, United States

MSKCC-Bergen ( Site 0162)

🇺🇸

Montvale, New Jersey, United States

The Center For Cancer And Blood Disorders ( Site 0151)

🇺🇸

Fort Worth, Texas, United States

Mercy Clinic Oncology and Hematology ( Site 0110)

🇺🇸

Oklahoma City, Oklahoma, United States

Renovatio Clinical ( Site 0117)

🇺🇸

The Woodlands, Texas, United States

Virginia Oncology Associates ( Site 0164)

🇺🇸

Virginia Beach, Virginia, United States

IC La Serena Research ( Site 0511)

🇨🇱

La Serena, Coquimbo, Chile

Fundacion Arturo Lopez Perez ( Site 0500)

🇨🇱

Santiago, Region M. De Santiago, Chile

Centre Jean Perrin ( Site 1003)

🇫🇷

Clermont-Ferrand Cedex 01, Puy-de-Dome, France

Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe ( Site 1200)

🇩🇪

Muenchen, Bayern, Germany

Universitaetsklinikum AoeR Duesseldorf ( Site 1210)

🇩🇪

Duesseldorf, Nordrhein-Westfalen, Germany

Universitaetsklinikum Mannheim GmbH ( Site 1213)

🇩🇪

Mannheim, Baden-Wurttemberg, Germany

Universitaetsklinikum Erlangen ( Site 1201)

🇩🇪

Erlangen, Bayern, Germany

Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1608)

🇭🇺

Kecskemét, Bacs-Kiskun, Hungary

Frauenklinik St. Louise ( Site 1216)

🇩🇪

Paderborn, Nordrhein-Westfalen, Germany

St Vincents University Hospital ( Site 0900)

🇮🇪

Dublin, Ireland

Aichi Cancer Center Hospital ( Site 2202)

🇯🇵

Nagoya, Aichi, Japan

Hyogo College of Medicine Hospital ( Site 2203)

🇯🇵

Nishinomiya, Hyogo, Japan

Fukushima Medical University Hospital ( Site 2201)

🇯🇵

Fukushima, Japan

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research (Site 2200)

🇯🇵

Osaka, Japan

National Cancer Center ( Site 2406)

🇰🇷

Goyang-si, Kyonggi-do, Korea, Republic of

Kyungpook National University Chilgok Hospital ( Site 2402)

🇰🇷

Daegu, Taegu-Kwangyokshi, Korea, Republic of

Ajou University Hospital ( Site 2407)

🇰🇷

Suwon-si, Kyonggi-do, Korea, Republic of

Gachon University Gil Medical Center ( Site 2408)

🇰🇷

Incheon, Korea, Republic of

Samsung Medical Center ( Site 2405)

🇰🇷

Seoul, Korea, Republic of

Hospital Universitario Reina Sofia ( Site 0705)

🇪🇸

Cordoba, Andalucia, Spain

Instituto Oncologico Baselga.Hospital Quiron. ( Site 0707)

🇪🇸

Barcelona, Spain

Hospital Universitari Vall d Hebron ( Site 0701)

🇪🇸

Barcelona, Spain

Chernihiv Medical Center of Modern Oncology ( Site 1520)

🇺🇦

Chernihiv, Chernihivska Oblast, Ukraine

Medical Centre Consilium Medical ( Site 1514)

🇺🇦

Kyiv, Kyivska Oblast, Ukraine

Medical center of the Limited Liability Company Yulis ( Site 1517)

🇺🇦

Zaporizhzhia, Zaporizka Oblast, Ukraine

North West Cancer Centre ( Site 0922)

🇬🇧

Londonderry, London, City Of, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath